Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Pulmonary Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Pulmonary Other
    On-Demand versus Routine Radiographs for Ventilated Patients Has Benefits in Clinical Practice - (DGNews)
    Inhaled Nitric Oxide Therapy for Preemies Does Not Improve Long-Term Outcomes - (DGNews)
    Low-Dose Radiation Angiograms Successful in Diagnosing Congenital Lung Lesions in Neonates: Presented at AAP - (DGDispatch)
    Lung Scintigraphy More Reliable Than CTA in Excluding Pulmonary Embolism in Pregnant Women - (DGNews)
    Ulinastatin Effective in Treating Impairment of Pulmonary Gas Exchange After Lower Extremity Surgery: Presented at ASA - (DGDispatch)

    News archive

     Recent webcasts/CME - Pulmonary Other
      Emerging Occupational and Environmental Respiratory Diseases
      PreAnesthetic Assessment of the Patient for Lung Resection
      Shared Decision Making in Patients with Pulmonary Nodules
      Update on DVT and PE in OB Gyn/Ortho Patients
      Interventional Pulmonology

      Webcasts/CME archive

       Recent cases - Pulmonary Other
        Multiorgan Paradoxical Embolism Consequent to Acute Pulmonary Thromboembolism with Patent Foramen Ovale: A Case Report
        Yellow Nail Syndrome
        Recurrent Spontaneous Pneumothorax During Pregnancy: A Case Report
        Rapid Resolution of Nitrofurantoin-Induced Interstitial Lung Disease
        A Tile Factory Worker Presenting with Breathlessness and Dry Cough

        Cases archive
          




        my personal edition > pulmonary other > news
        divider

          E-Mail this DGNews to a colleague

        DGNews


        First and Only Oral Medication Approved for Pulmonary Arterial Hypertension in HIV Patients

        MONTREAL, CANADA -- July 24, 2006 -- TracleerŪ (bosentan) is now indicated by Health Canada for patients with pulmonary arterial hypertension (PAH) secondary to HIV in those who did not respond adequately to conventional therapy.

        PAH is a life-threatening lung disease associated with elevated blood pressure inside the pulmonary artery. PAH patients typically present with unexplained symptoms such as fatigue, breathlessness, chest pain and fainting. People living with HIV are six to 12 times more likely to contract PAH than the uninfected population. Although there are a number of theories as to why this happens, the precise reasons remain unknown.[i]

        This new indication for TracleerŪ adds another separate and difficult patient population to those PAH patients who can benefit from the drug. TracleerŪ had previously been approved in Canada for the treatment of patients with functional class III and IV (meaning a moderate to severe form of the disease) primary PAH and PAH secondary to scleroderma. It can offer significant clinical benefits including improvements in exercise capacity and a decrease in the rate of clinical worsening.

        TracleerŪ is the only approved oral treatment in Canada that blocks the body's endothelin receptors. Endothelin is a substance produced by the endothelial cells that form a layer lining the blood and lymph vessels. It has the effect of narrowing the blood vessels and can also harden tissues, causing scarring. Endothelin is known to be a key component in the development of PAH.

        A study evaluating the impact of starting treatment with TracleerŪ on the survival of primary PAH patients has shown that 96% of patients were alive after one year and 89% were alive after two years. This is compared to a predicted one and two year survival of 69% and 57% respectively based on National Institutes of Health (NIH) registry formula.

        "It is a reassuring development that bosentan is now approved for patients who have PAH secondary to HIV, as this is a population for whom specific therapy for PAH was not available. Similar to other patients with PAH, people with HIV can become quite ill and die from their disease" said Dr. John Granton, Respirologist, Toronto General Hospital.

        About Pulmonary Arterial Hypertension (PAH)
        PAH is a rare and life-threatening disease characterized by abnormally high blood pressure in the pulmonary artery, the blood vessel that carries oxygen-poor blood from the right side of the heart to the lungs. In PAH, there is increased blood flow resistance in the pulmonary arteries, raising pressure and forcing the right side of the heart to work harder. The heart muscle starts to weaken, resulting in right-heart failure. There are a number of treatment options for PAH, although not yet a cure.

        Important Safety Information
        In clinical trials leading to the marketing approval of bosentan, approximately 11% of PAH patients receiving the drug experienced abnormal but reversible liver enzyme elevations. It is therefore important that patients undergo monthly liver monitoring. Due to the risk of birth defects, women who are pregnant, or of childbearing age who do not use a reliable method of contraception, must not take bosentan.

        Tracleer is a registered trademark of Actelion Pharmaceuticals Ltd, CH-4123
        Allschwil, Switzerland.

        REFERENCE:
        [i] http://aids-clinical-care.jwatch.org/cgi/content/full/2001/601/6, accessed January 24, 2006.


        SOURCE: Actelion



        E-Mail this DGNews to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send